« Return to News | CROs/Service Providers

ShangPharma’s shareholders approve merger agreement

Monday, March 25, 2013 10:02 AM

China-based pharmaceutical and biotechnology R&D outsourcing company ShangPharma’s shareholders have voted in favor of merger agreement in which ShangPharma Merger Sub will merge with ShangPharma, with the new entity being a wholly owned subsidiary of ShangPharma Parent.

Of the Company's ordinary shares entitled to vote at the extraordinary general meeting, approximately 82.6% of such shares were voted in person or by proxy, with approximately 99.9% of those shares voting in favor of the proposal to approve the merger agreement.

Completion of the merger is subject to the satisfaction or waiver of the conditions set forth in the merger agreement. The Company will work with the various other parties to the merger agreement to satisfy all other conditions precedent to the merger set forth in the merger agreement and complete the merger as quickly as possible. If and when completed, the merger would result in the Company becoming a privately held company and its American depository shares, each representing eighteen Company ordinary shares, would no longer be listed on the New York Stock Exchange.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.